Certara (NASDAQ:CERT) Earns Overweight Rating from Stephens

Certara (NASDAQ:CERT)‘s stock had its “overweight” rating reissued by research analysts at Stephens in a research note issued to investors on Thursday,Benzinga reports. They presently have a $17.00 price objective on the stock. Stephens’ target price suggests a potential upside of 37.71% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Robert W. Baird reduced their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. TD Cowen started coverage on Certara in a research report on Thursday. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Barclays lowered their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.64.

Certara Stock Up 0.1 %

Shares of NASDAQ:CERT opened at $12.35 on Thursday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -61.95, a PEG ratio of 9.29 and a beta of 1.57. Certara has a 12-month low of $9.41 and a 12-month high of $19.87. The business has a 50-day moving average price of $12.39 and a 200 day moving average price of $11.63. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Institutional Trading of Certara

A number of large investors have recently modified their holdings of the stock. ArrowMark Colorado Holdings LLC grew its stake in Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after purchasing an additional 3,861,674 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Certara by 864.0% in the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock valued at $40,253,000 after buying an additional 3,387,590 shares during the period. Brown Brothers Harriman & Co. acquired a new position in shares of Certara during the third quarter worth about $27,292,000. Mackenzie Financial Corp purchased a new stake in shares of Certara during the fourth quarter worth approximately $17,852,000. Finally, Wasatch Advisors LP raised its holdings in Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after acquiring an additional 1,651,076 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.